Agfa account plan
Innovative Imaging IT Solutions
At a glance
Agfa-Gevaert is a Belgian imaging-technology group in healthcare IT, film and green hydrogen membranes: FY2025 revenue 1,086 million euro, 4,211 employees.
Agfa-Gevaert, headquartered in Mortsel, Belgium, develops, manufactures and sells analog and digital imaging systems for hospitals and imaging networks, the printing industry, the green hydrogen industry and industrial applications. It has production and research centres in Belgium, the United States, Canada, the United Kingdom, Austria and China, and sales organisations in more than 30 countries. FY2025 revenue was 1,086 million euro (-4.5%), adjusted EBITDA 59 million euro and the net result -71 million euro; it had 4,211 employees, 69% of them in Europe. It is listed (market capitalisation 78 million euro at 31 December 2025), its largest disclosed shareholder is Active Ownership Capital (15-20%), and since Q3 2026 its continuing operations are two segments, HealthCare IT and Imaging and Advanced Materials, with Digital Printing Solutions being combined with EFI.
Business units
HealthCare IT (Agfa HealthCare)
21% of FY2025 revenue (232 million euro)Sells the Enterprise Imaging Platform (PACS, XERO Universal Viewer, Vendor Neutral Archive, workflow orchestration and AI) to hospitals, health systems and imaging networks, increasingly as the Enterprise Imaging Cloud SaaS offer, with a push into North America. In Q3 2026 revenue rose 11.2% to 56 million euro, 12-month order intake reached 197 million euro and recurring revenue was 69% of revenue. Led by Nathalie McCaughley, President Agfa HealthCare.
Imaging and Advanced Materials
roughly about EUR 600 million of annual sales (CFO, Q3 2026 call)Created in Q3 2026 from Film and Chemicals (about 80% of the segment: medical and industrial X-ray film, PCB films, conductive polymers, synthetic paper), Digital Radiology Solutions (CR and DR systems, DRYSTAR printers, MUSICA image processing) and Green Hydrogen Solutions (ZIRFON separator membranes for alkaline electrolysis). Q3 2026 revenue fell 3.4% to 155 million euro with adjusted EBITDA of -1.4 million euro, as ZIRFON fell 82.2% and Digital Radiology Solutions 8.4% while silver-driven film prices offset volume declines.
Digital Printing Solutions (discontinued)
193 million euro of FY2025 revenueWide-format and industrial inkjet printers (Anapurna, Jeti, Onset, SpeedSet), inks, workflow software and services for sign & display and packaging printers. Q3 2026 revenue fell 10.2% to 42 million euro on equipment, while ink sales rose 12%. It is to be combined with EFI, with Siris owning 60% and Agfa 40%, closing expected by end-2026. Led by Vincent Wille.
Strategic priorities
- Cloud and SaaS transition in HealthCare IT
- Move Enterprise Imaging to the cloud and win share in North America; 12-month cloud order intake more than tripled to 90.7 million euro by Q3 2026. Management sees 2028 as the pivot year and EBITDA margins of 20-25% once the business is mainly cloud/SaaS.
- Shrink the film cost base
- A self-funding programme (internally Moonshot, the restructuring of Mortsel operations) targets 50 million euro of savings by end-2027; annualised savings reached 64 million euro by Q3 2026 and production headcount was almost halved.
- Green hydrogen with ZIRFON
- ZIRFON membranes are described as a core pillar of the growth strategy; a new plant opened in September 2025, and after a weak 2026 the company expects a significant upturn in 2027 driven by projects that reached FID and demand in China and India.
- Liquidity first
- The CEO called liquidity the first priority while the next couple of years remain transformation years; the 180 million euro RCF was extended to 1 August 2030 and a receivables factoring programme was started with BNP Paribas Fortis.
- Portfolio reshaping
- Digital Printing Solutions is being combined with EFI into a jointly held company, and the CEO said the group is always looking at strategic options while the cloud transition remains the first priority.
Latest results
In Q3 2026 continuing revenue was stable at 210 million euro, but adjusted EBITDA fell to 1 million euro (4 in Q3 2025) as savings and price increases did not fully offset lower volumes in film, Direct Radiography and green hydrogen; the net result was -24 million euro. Over nine months, revenue was 631 million euro (-2.5%) and adjusted EBITDA 25 million euro (+18%). HealthCare IT improved, with revenue up 11.2% and adjusted EBITDA of 5.5 million euro. Q3 free cash flow was -14 million euro after 16 million euro of transformation cash-outs, and net financial debt (excl. IFRS 16) rose to 92 million euro. For 2026 the company expects HealthCare IT profitability below last year because of the faster cloud shift, lower revenue and profitability in Imaging and Advanced Materials, and free cash flow more negative than 2025.
Investments and deals
- DPS combination with EFI
- Agreement signed on 28 September 2026 to combine Digital Printing Solutions with EFI, a Siris portfolio company; Siris will own 60% and Agfa 40%, with closing expected by end-2026.
- New ZIRFON plant
- A new ZIRFON membrane production facility opened in September 2025, backed by 11 million euro from the EU Innovation Fund, and a long-term innovation agreement was signed with VITO.
- Film restructuring
- Restructuring expenses were 54 million euro in 2025, including the Belgian plant reorganisation (29) and the closure of Bushy Park in the US (9); the programme affects 470 employees in Belgium in phase 1 and up to 145 more.
- HealthCare IT R&D and AI
- HealthCare IT spends close to EUR 40 million a year on R&D; AI is used in coding (30-50% productivity gains), diagnosis and workflow orchestration.
Challenges and risks
- Declining medical film market
- Radiology Solutions revenue fell 17.1% in 2025 as medical film declined, particularly in China, and a 28 million euro impairment was booked; film volumes kept falling in 2026.
- Silver price volatility
- Silver moved from $88 to $62 an ounce in 2026, adding 45 million euro of nine-month sales but costing just over 30 million euro of cash; it is managed through price indexation and leaner inventories.
- Green hydrogen delays
- ZIRFON revenue fell 82.2% in Q3 2026 after REDIII delays in Europe and new delays from the leaked RED IV proposal.
- Cloud transition weighs on margins
- The SaaS shift lowers short-term revenue and margins; the CEO said a SaaS contract catches up with a project contract after about four and a half years.
- Debt, pensions and cash burn
- Total debt was 450 million euro at Q3 2026, including net pension debt of 320 million euro, and free cash flow is expected to stay negative during the transformation.
What leadership says
“We are determined to make green hydrogen an industrial reality.”
“Our savings initiatives and operational discipline are delivering tangible results, while the growing adoption of our cloud-based HealthCare IT solutions reinforces our confidence in the growth potential of the business.”
“We are one of the few players with a good track record of bringing Enterprise Imaging to the cloud.”
“I still see the next couple of years to be transformation years, where we will have to spend still a significant amount in restructuring.”
Where a supplier can help
- Cloud migration and hosting for Enterprise Imaging
- Tied to the HealthCare IT cloud and SaaS transition: suppliers of cloud infrastructure, migration services and managed operations can help convert the installed base and lower the cost to serve.
- Cash and working-capital tools
- Tied to the liquidity-first priority and silver-driven working capital: treasury, inventory planning (S&OP) and receivables financing offers fit a group that is already factoring and reviewing vendor financing.
- Cost reduction in film operations
- Tied to the self-funding film programme: automation, outsourcing and procurement services can support further savings in Mortsel operations as volumes decline.
- Healthcare AI and workflow partners
- Tied to HealthCare IT R&D and AI investment: third-party diagnostic and workflow applications can integrate with the cloud platform.
- Green hydrogen project support
- Tied to the expected 2027 ZIRFON rebound in China, India and Europe: logistics, local distribution and electrolyser-project partners can help capture demand as projects reach FID.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Agfa?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Agfa-Gevaert Annual Report 2025
- Agfa-Gevaert is a Belgian imaging-technology group (HQ Mortsel) with nearly 160 years of history. In FY2025 it reported three divisions plus CONOPS: HealthCare IT (21% of revenue), Digital Print & Chemicals (43%), Radiology Solutions (29%) and CONOPS (7%, supply agreements with the former Offset business, now ECO3).
- FY2025 revenue was 1,086 million euro (-4.5%; -2.7% excluding currency). Adjusted EBITDA fell from 70 to 59 million euro (5.5% of revenue), the net result was -71 million euro (2024: -92) and free cash flow was +35 million euro.
- HealthCare IT (Enterprise Imaging) is moving to cloud/SaaS in North America. Order intake rose 14% to 187 million euro, cloud was 33% of order intake (Q4: 58%), net new customers made up 43%, and the adjusted EBITDA margin was 14.5%. The division won Best in KLAS awards for XERO Viewer and VNA.
- Digital Print & Chemicals grew revenue 6.5% to 467 million euro and lifted its adjusted EBITDA margin to 9.1%. Specialty Films & Chemicals (PCB films) and ZIRFON hydrogen membranes grew, while Digital Printing Solutions fell 2.4% on weak equipment investment. A new ZIRFON plant was inaugurated in September 2025.
- Radiology Solutions revenue fell 17.1% to 317 million euro as the medical film market declined, particularly in China. Adjusted EBITDA swung to -9.1 million euro and a 28 million euro impairment was booked on the Radiology Solutions cash-generating unit.
- A self-funding film cost-base programme is expected to deliver 50 million euro of savings by end-2027 (470 employees in Belgium in phase 1, up to 145 more announced). Restructuring expenses were 54 million euro in 2025.
- From 1 January 2026 the group reports three segments: HealthCare IT, Industrial Solutions and Imaging & Chemicals. CEO is Pascal Juéry and Chairman is Frank Aranzana.
- 2026 outlook: HealthCare IT profitability broadly in line with 2025 and order intake growing; Industrial Solutions held back by delays in green hydrogen; Imaging & Chemicals profitability improving. Group free cash flow is expected to be negative because of transformation cash-outs.
- Balance sheet at end-2025: net financial debt (excl. IFRS 16) of 21 million euro, total net debt (incl. pensions) of 422 million euro, a 180 million euro RCF with 100 million drawn, and equity of 256 million euro. The market capitalisation was 78 million euro at 31 December 2025.
- Agfa-Gevaert in Q2 2026: resilient performance amid market challenges (H1 2026 results)
- Q2 2026 revenue was 275 million euro (-0.7% excluding currency). H1 2026 revenue was 512 million euro (+0.4% excluding currency). Q2 adjusted EBITDA was 14 million euro (13 in Q2 2025), and H1 adjusted EBITDA rose to 25 million euro from 15.
- The Q2 net result was -15 million euro, against +30 million euro in Q2 2025 (boosted then by the AgfaPhoto arbitration award). Q2 free cash flow was -10 million euro after 30 million euro of restructuring and transformation cash-outs.
- Annualised savings of 61 million euro had been realised by the end of Q2. The group says its cost base is "now in line with the market evolution".
- HealthCare IT: 12-month rolling order intake rose 27.5% to 192 million euro, cloud was 51% of Q2 order intake (4% in Q2 2025), and recurring revenue was 66% of revenue. Revenue fell 9.5% (ex-currency) to 54 million euro and adjusted EBITDA was 5.3 million euro. Wins include RUSH University System for Health.
- Industrial Solutions: Digital Printing Solutions grew 10.8% ex-currency and ink sales rose 10%, but Green Hydrogen Solutions (ZIRFON) fell 77% in a soft market. Segment adjusted EBITDA was 2.5 million euro.
- Imaging and Chemicals: revenue rose 2.6% ex-currency because silver-driven film price increases offset falling volumes. Adjusted EBITDA jumped to 8.9 million euro from 3.7 thanks to the savings programmes.
- AgfaPhoto: a Frankfurt court annulled the ICC award on 29 May 2026 on procedural grounds and remitted the case. Agfa has appealed to the German Federal Court of Justice; it had received about 45 million euro under the award.
- Net financial debt (excl. IFRS 16) was 74 million euro, 130 million euro of the 180 million euro RCF was drawn, and a 20 million euro receivables factoring programme was started with BNP Paribas Fortis. FY2026 free cash flow is expected to be more negative than 2025.
- Agfa-Gevaert in Q3 2026: Executing Transformation Despite Challenging Markets
- Agfa agreed on 28 September 2026 to combine its Digital Printing Solutions (DPS) business with EFI, a Siris portfolio company. Siris will own 60% of the new company and Agfa 40%, as equal governance partners, with closing expected by end-2026. DPS is now reported as discontinued operations.
- New segment reporting: continuing operations are HealthCare IT and a new Imaging and Advanced Materials segment (Green Hydrogen Solutions, Film and Chemicals, Digital Radiology Solutions).
- Q3 2026 continuing revenue was stable at 210 million euro, while adjusted EBITDA fell to 1 million euro (4 in Q3 2025). Over nine months, revenue was 631 million euro (-2.5%) and adjusted EBITDA 25 million euro (+18%). The Q3 net result was -24 million euro.
- HealthCare IT: revenue rose 11.2% to 56 million euro and adjusted EBITDA to 5.5 million euro (9.8% margin). 12-month order intake was 197 million euro (+21%), cloud orders tripled to 90.7 million euro, and recurring revenue reached 69% of revenue. New cloud customers include Rush and Infirmary Health.
- Imaging and Advanced Materials: revenue fell 3.4% to 155 million euro and adjusted EBITDA was -1.4 million euro. ZIRFON revenue fell 82.2%, Digital Radiology Solutions fell 8.4%, and film volume declines were offset by silver-driven prices.
- Annualised savings reached 64 million euro. Q3 free cash flow was -14 million euro, mainly from 16 million euro of transformation cash-outs. Net financial debt (excl. IFRS 16) was 92 million euro, with 160 million euro of the RCF drawn. The RCF was extended to 1 August 2030.
- Outlook 2026: HealthCare IT profitability below last year because the cloud shift is faster than expected; Imaging and Advanced Materials revenue and profitability down; DPS up. Full-year free cash flow is expected to be more negative than 2025.
- Agfa-Gevaert Q3 2026 results conference call (transcript)
- CEO Pascal Juéry and new CFO Declan Guerin presented Q3 2026 (10 November 2026), the first quarter with DPS reported as discontinued ahead of its combination with EFI. Juéry said "the transformation of the group is on track".
- HealthCare IT: 12-month order intake of 197 million euro, about double the roughly 100 million euro of five years ago, with cloud at 91 million euro, mostly from new logos (at least "two, three, four per quarter"). Recurring revenue was 69% of sales, "the highest number ever".
- Juéry explained the cloud J-curve: a SaaS contract catches up with a project contract's revenue after about four and a half years. The faster shift lowers 2026 profitability, 2027 continues the same pattern, and 2028 should be the pivot year. He sees HealthCare IT EBITDA margins of 20-25% over time.
- Imaging & Advanced Materials is "roughly about EUR 600 million of annual sales", about 80% Film & Chemicals. Silver price swings ($88 to $62 an ounce in 2026) added 45 million euro of 9-month sales and 5 million euro of gross margin, and cost just over 30 million euro of cash.
- Silver is managed through price indexation (about a one-quarter lag), leaner silver inventories, steadier purchasing ("physical hedging") and a review of vendor financing and factoring.
- Green hydrogen had "almost ... a blank year in 2026", but customers' FIDs give visibility of "a very significant rebound" in 2027, probably not yet at 2025 levels.
- On restructuring, Juéry said production headcount was "almost divided by two" and that further cuts will come "at a slower pace". He expects "the next couple of years" to remain transformation years with cash spent on restructuring, and called liquidity the first priority.
- On EFI/DPS, he said "there is probably an underestimation about the amount of value creation" and expects "significant economic value for the group in the next three years".
- Agfa-Gevaert Q2 2026 results conference call (transcript)
- On the Q2 2026 call (26 August 2026), CEO Pascal Juéry announced that CFO Fiona Lam would leave at the end of the month and that Declan Guerin starts on 1 October. He described "pretty resilient results, but a lot of moving parts".
- HealthCare IT: 50% of Q2 order intake was cloud and 54% came from net new customers ("we are winning share ... against the market leaders"). Juéry said "we will break the EUR 200 million mark" in order intake.
- HealthCare IT spends "close to EUR 40 million" a year on R&D on a business of "about EUR 240 million". AI is used in coding (30-50% productivity gains), in diagnosis and in workflow orchestration, and third-party applications can be integrated.
- DPS is back to double-digit growth in the high end and ink sales are up 10%. ZIRFON is in "a trough": customers hold membrane inventory, with a "very sizable rebound" expected in 2027 and first sales in China and India.
- Film & Chemicals has "turned a corner" because restructuring savings more than offset volume declines. The restructuring programme, internally called Moonshot (Mortsel operations), is "self-funding", with more than EUR 60 million of recurring savings roughly matching its cost.
- H1 adjusted EBITDA was EUR 10 million higher year on year. H1 free cash flow was -EUR 52 million, including about EUR 45 million spent buying silver for inventory.
- AgfaPhoto: the Frankfurt annulment concerns procedure, not substance. Agfa has appealed and "we keep the money" (about EUR 45 million).
- Asked whether new board member Kurt Decat and the new CFO's carve-out backgrounds point to a HealthCare IT separation, Juéry said "we are always looking at strategic options". He called the question legitimate but said the cloud transition is the first priority.
Questions about Agfa
What does Agfa-Gevaert do?
Agfa-Gevaert is a Belgian imaging-technology group. It sells enterprise imaging software to hospitals, X-ray film and digital radiography systems, specialty films and chemicals, and ZIRFON membranes for green hydrogen electrolysis.
What is Agfa-Gevaert's revenue?
FY2025 revenue was 1,086 million euro, down 4.5%, with adjusted EBITDA of 59 million euro and a net result of -71 million euro. Nine-month 2026 revenue from continuing operations was 631 million euro.
How many employees does Agfa-Gevaert have?
It had 4,211 employees in 2025, 69% of them in Europe and 16% in North America.
Who leads Agfa-Gevaert?
Pascal Juéry is CEO and Frank Aranzana chairs the board. Declan Guerin became CFO on 1 October 2026.
What is Agfa-Gevaert's strategy?
It is moving HealthCare IT to cloud and SaaS, shrinking its film cost base through a self-funding savings programme, betting on ZIRFON for green hydrogen, and combining Digital Printing Solutions with EFI.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)